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Plasma native and peptidase-derivable Met-enkephalin
responses to restraint stress in rats. Adaptation to repeated
restraint.
K Pierzchala, G R Van Loon
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Met-enkephalin and related proenkephalin A-derived peptides circulate in plasma at picomolar concentration as free,
native pentapeptide and at nanomolar concentration in cryptic forms. We have optimized conditions for measurement of
immunoreactive Met-enkephalin in plasma and for generation by trypsin and carboxypeptidase B of much greater
amounts of total peptidase-derivable Met-enkephalin in plasma of rats, dogs, and humans. Free Met-enkephalin (11 pM)
is constituted by native pentapeptide and its sulfoxide. Characterization of plasma total Met-enkephalin derived by
peptidic hydrolysis revealed a small amount (38 pM) of Met-enkephalin associated with peptides of molecular mass less
than 30,000 D, and probably derived from proenkephalin A, but much larger amounts of Met-enkephalin associated with
albumin (1.2 nM) and with a globulin-sized protein (2.8 nM). Thus, plasma protein precursors for peptidase-derivable Met-
enkephalin differ structurally and chemically from proenkephalin A. Met-enkephalin generated from plasma by peptidic
hydrolysis showed naloxone-reversible bioactivity comparable to synthetic Met-enkephalin. Prolonged exposure of adult,
male rats to restraint stress produced biphasic plasma responses, with peaks occurring at 30 s and 30 min in both free
native and total peptidase-derivable Met-enkephalin. Repeated daily exposure to this 30-min stress resulted in adaptive
loss of responses of both forms to acute restraint. Initial plasma responses of Met-enkephalin paralleled those of
epinephrine and norepinephrine, but subsequently showed divergence of response. In conclusion, Met-enkephalin
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Responses to Restraint Stress in Rats
Met-Enkephalin
Adaptation to Repeated Restraint
Krystyna Pierzchala and Glen R. Van Loon
Division of Endocrinology and Metabolism, Department of Medicine, University of Kentucky and
Veterans Administration Medical Center, Lexington, Kentucky 40536
Abstract
Met-enkephalin and related proenkephalin A-derived peptides
circulate in plasma at picomolar concentration as free, native
pentapeptide and at nanomolar concentration in cryptic forms.
Wehave optimized conditions for measurement of immunore-
active Met-enkephalin in plasma and for generation by trypsin
and carboxypeptidase B of much greater amounts of total pep-
tidase-derivable Met-enkephalin in plasma of rats, dogs, and
humans. Free Met-enkephalin (11 pM) is constituted by native
pentapeptide and its sulfoxide. Characterization of plasma
total Met-enkephalin derived by peptidic hydrolysis revealed a
small amount (38 pM) of Met-enkephalin associated with
peptides of molecular mass < 30,000 D, and probably derived
from proenkephalin A, but much larger amounts of Met-en-
kephalin associated with albumin (1.2 nM) and with a globu-
lin-sized protein (2.8 nM). Thus, plasma protein precursors for
peptidase-derivable Met-enkephalin differ structurally and
chemically from proenkephalin A. Met-enkephalin generated
from plasma by peptidic hydrolysis showed naloxone-revers-
ible bioactivity comparable to synthetic Met-enkephalin.
Prolonged exposure of adult, male rats to restraint stress
produced biphasic plasma responses, with peaks occurring at
30 s and 30 min in both free native and total peptidase-deriv-
able Met-enkephalin. Repeated daily exposure to this 30-min
stress resulted in adaptive loss of responses of both forms to
acute restraint. Initial plasma responses of Met-enkephalin
paralleled those of epinephrine and norepinephrine, but subse-
quently showed divergence of response. In conclusion, Met-en-
kephalin circulates in several forms, some of which may be
derived from proteins other than proenkephalin A, and plasma
levels of both free native, and peptidase-derivable Met-en-
kephalin are modulated physiologically. (J. Clin. Invest. 1990.
85:861-873.) proenkephalin A peptides * plasma opioid pep-
tides * plasma neuropeptides * plasma sympathoadrenal
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Introduction
Met-Enkephalin and a number of proenkephalin A-derived
peptides are widely distributed within the central nervous sys-
tem and in many peripheral tissues including adrenal medulla,
sympathetic nerve terminals and ganglia, pancreas, gastroin-
testinal tract, and pituitary (1, 2). Co-secretion of enkephalin-
related peptides and catecholamines has been demonstrated
from chromaffin cells in vitro, from isolated perfused adrenal
glands and from adrenal gland in vivo (3-7). Although circu-
lating Met-enkephalin has been quantitated by a number of
laboratories, considerable variability in plasma concentration
has been described (8). Met-enkephalin is degraded rapidly in
plasma and changes in circulating levels in response to stimuli
have been difficult to document. Indeed, very little is known
regarding the in vivo regulation of secretion of Met-enkepha-
lin-related peptides and of the plasma levels of Met-enkepha-
lin. It has been shown clearly that in a number of tissues,
including adrenal medulla and brain, enkephalin-containing
peptides are converted to Met-enkephalin in a series of enzy-
mic steps which involve processing by trypsinlike and car-
boxypeptidase B-like enzymes (9-1 1). The Met-enkephalin in
such peptides derived from proenkephalin A has been referred
to as cryptic Met-enkephalin. It remains unclear whether Met-
enkephalin is secreted into the circulation only as a pentapep-
tide or whether it may be secreted also in a larger protected
form, and later hydrolyzed to the pentapeptide. In addition
and analogous to other hormones, it seems probable that Met-
enkephalin also circulates in a bound form, in association with
albumin or a globulin.
The physiological relevance of circulating Met-enkephalin
remains poorly understood. Inferences have been made from
studies employing the opioid antagonist, naloxone. However,
conclusions regarding effects of circulating Met-enkephalin,
which can be drawn from such studies, have been necessarily
limited since naloxone acts at receptors in both periphery and
brain and since other circulating endogenous opioids such as
fl-endorphin might mediate such naloxone-antagonizable ef-
fects. Clearly, in order to better document the physiology of
Met-enkephalin acting as a hormone, studies of its circulating
forms and their regulation are essential. Thus, during the past
few years we have determined to measure immunoreactive
Met-enkephalin in plasma, to define more optimal enzymic
conditions for the generation of peptidase-derivable Met-en-
kephalin in plasma, to characterize the large circulating forms
of peptidase-derivable Met-enkephalin, and to define iin rats
the physiologic regulation of plasma responses to a psychologi-
cal stress of free native Met-enkephalin and total peptidase-
derivable Met-enkephalin.
Methods
Materials. Met-O-enkephalin sulfoxide, L-l-tosylamide-2-phenylethyl
chloromethyl ketone (TPCK)'-treated trypsin, carboxypeptidase B,
1. Abbreviations used in this paper: TPCK, L-l-tosylamide-2-phenyl-
ethyl chloromethyl ketone.
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trypsin inhibitor, rabbit y-globulin, DL-dithiothreitol (DTT), EGTA,
Sephadex G-200 fine, Tris-HCl, sodium azide, bovine serum albumin,
propylene glycol, and chloral hydrate were obtained from Sigma
Chemical Co., St. Louis, MO. Met-enkephalin, Leu-enkephalin, Tyr-
Gly-Gly-Phe, Gly-Gly-Phe-Met, Met-enkephalin-Arg6-Phe7, Met-en-
kephalin-Arg6-Gly7-Leu8, metorphamide, peptide B, peptide
BAM-12P, peptide E, and peptide F were obtained from Peninsula
Laboratories, Inc., Belmont, CA. Porapak Q (80-120 mesh) was ob-
tained from Waters Associates-Millipore, Milford, MA; aprotinin
(Trasylol) from Mobay, New York, and polyethyleneglycol (PEG),
molecular mass 8,000 D, from Aldrich Chemical Co., Milwaukee, WI.
Commercial antiserum, anti-Met-enkephalin 18R2, was obtained
from Immunonuclear Corp., Stillwater, MN, and '25I-Met-enkephalin
was obtained from New England Nuclear-Dupont, Wilmington, DE.
Disodium EDTA, citric acid, sodium phosphate monobasic and diba-
sic, and magnesium sulfate were obtained from Fisher Scientific Co.,
Fair Lawn, NJ; Spectrapor membrane tubing from Spectrum Medical
Industries, Los Angeles, CA; Affi-Gel Blue (50-100 mesh wet) from
Bio-Rad Laboratories, Richmond, CA; and Diaflo Ultrafilters PM30
and Centricon- 100 from Amicon Corp., Danvers, MA. Eqithesin was
made from 2.13 g of chloral hydrate, 1.04 g magnesium sulfate, 14.1
ml of propylene glycol, 9.75 ml of Nembutal, 3.78 ml of ethanol, and
adjusted to 50 ml in volume with 22.4 ml of water.
Collection of blood. Blood for Met-enkephalin estimation was col-
lected on ice in polypropylene tubes in EDTA2.7 nmol/ml of blood,
citric acid 17.7 umol/ml of blood, and aprotinin 200 kIU/ml blood
(12). Blood was centrifuged at 40,000 g for 30 min at 4°C, then plasma
was acidified with 0.5 N HC1 final concentration, and stored at -70°C
until assay. Blood for norepinephrine and epinephrine to be measured
by a single-isotope radioenzymatic assay (13) was collected into chilled
polypropylene tubes containing 2 mgof DTTand 10 Ml of 10% EGTA.
Blood was centrifuged at 30,000 g for 10 min and the deproteinized
plasma was stored at -70°C until assay.
Extraction of native Met-enkephalin from plasma. Acidified
plasma, 300 Al, was neutralized with 2 ml of 0.06 Mphosphate buffer,
pH 10.2; this phosphate buffer was prepared from sodium phosphate
monobasic 0.07 Mand sodium phosphate dibasic 0.05 M, then pH
adjusted with sodium hydroxide 10 N. Samples were applied to Pora-
pak Qcolumns composed of 250 mgof Porapak Q in 3 ml of absolute
ethanol (200 proof). Porapak Q slurry was prepared by degassing
overnight 25 g in 350 ml of absolute ethanol. Shortly before applying
the samples, columns were equilibrated with 6 ml of doubly distilled
water; then loaded columns were washed with 3 ml of doubly distilled
water, and Met-enkephalin was eluted with 3 ml of absolute ethanol,
lyophilized overnight and assayed immediately.
Radioimmunoassay of Met-enkephalin in plasma. Commercial
Met-enkephalin antiserum 18R2 raised in rabbit was examined for
cross-reactivity with the following peptides: Met-O-enkephalin, Met-
enkephalin, Tyr-Gly-Gly-Phe, Gly-Gly-Phe-Met, Leu-enkephalin,
Met-enkephalin-Arg6-Phe7, Met-enkephalin-Arg6-Gly7-Leu8, metor-
phamide, peptide B, peptide BAM-12P, peptide E, and peptide F.
Lyophilized samples were reconstituted with 100 Ml of 0.06 M
phosphate buffer, pH 6.5, containing 0.2% of bovine serum albumin
and 0.002% sodium azide. 50 ,ul of antiserum diluted 1: 10,000 and 50
Ml of I25I-Met-enkephalin (- 1,500 cpm) were added and samples were
incubated at 4°C. After 24 h of incubation, 50 Ml of 1% rabbit y-globu-
lin were added and incubation was maintained at 4°C for 30 min.
Separation of bound from free complex was performed by adding 250
Ml of 25% PEG. After 30 min of incubation, samples were centrifuged
at 2000 g at 4°C for 30 min, supernatant was discarded, and pellets
were counted in y-counter (Packard Instrument Co., Inc., Downers
Grove, IL).
Recovery of Met-enkephalin from Porapak Qwas studied by ex-
traction of Met-enkephalin from phosphate buffer or plasma and com-
parison with unextracted Met-enkephalin standard. Recovery of im-
munoreactive Met-enkephalin standard from 0.5 NHCl was examined
after lyophilization at pH 6.0, reconstitution in buffer and extraction
with Porapak Qcolumns. Recovery of Met-enkephalin was also stud-
ied by comparing the recovery of '251-Met-enkephalin (- S pg) from
phosphate buffer or plasma. Parallelism of native endogenous Met-en-
kephalin with standard Met-enkephalin was demonstrated by compar-
ison with assay of 100-1,000 jA of each of rat, human, and dog plasma.
Further validation of the authenticity of this immunoreactive Met-
enkephalin was obtained by partial purification using reverse-phase
HPLCon a C18 column 0.39 X 30 cm preceded by a guard column 4.6
X 30 mm(both columns, Waters Associates) with two systems: 20%
acetonitrile in 0.1% trifluoroacetic acid, or 0.01 Mphosphate buffer/
methanol in a 70/30 ratio, at flow rates of 1-1.8 ml/min; 1-min frac-
tions were collected for RIA of Met-enkephalin. HPLCwas carried out
in this laboratory by Dr. A. A. Houdi.
Total peptidase-derivable Met-enkephalin in plasma. To release
Met-enkephalin from larger molecular forms present in plasma or
from Met-enkephalin bound to plasma protein (together with free
these comprise total Met-enkephalin), different conditions for enzymic
hydrolysis were compared. Plasma was incubated for 30 min at 370C
with TPCK-treated trypsin in concentrations of 300-2,000 ,ug/ml. Im-
mediately after, plasma was incubated for 15 min with carboxypepti-
dase B, 10-100 Ag/ml plus trypsin inhibitor 2.5 mg/ml. From different
combinations of trypsin and carboxypeptidase B described above, the
optimal conditions were determined (Table I). In subsequent studies
for preparation of total plasma Met-enkephalin, 50 Ml of acidified
plasma was treated with 75 A1 of Tris-base buffer 0.5 M, pH 9.6, to
bring pH to 7.8-8.0, then incubated with 50 Al of TPCK-treated tryp-
sin (1 mg/ml Tris-HCl, pH 7.7) in water bath at 370C for 30 min,
followed by further incubation for 15 min with 50 Ml of carboxypepti-
dase B (50 ,g/ml Tris-HCl) plus trypsin inhibitor 2.5 mg/ml. Enzymic
hydrolysis is stopped by addition of 250 Al of ice-cold Tris-HCl (pH
7.7) and placing samples on ice. Before applying to Porapak Q col-
umns, 500 ,l of 0.006 Mphosphate buffer, pH 6.0, is added to change
pH to 6.5, and samples are processed as described above for native
Met-enkephalin.
Parallelism of total endogenous Met-enkephalin released after en-
zymic hydrolysis with Met-enkephalin standard was demonstrated by
comparison with assay of 10-500 Ml of each of rat, human, and dog
plasma treated as described above with trypsin and carboxypeptidase
B. This peptidase-derivable (total) Met-enkephalin is extracted on
Porapak Qbefore radioimmunoassay.
Characterization of total peptidase-derivable Met-enkephalin in
plasma. Circulating total peptidase-derivable Met-enkephalin may be
derived from larger precursor peptides of molecular mass < 30,000 D,
which are in turn derived from preproenkephalin A, or may be derived
from other proteins unrelated to proenkephalin A but containing the
Met-enkephalin sequences, or may be bound to plasma protein car-
riers. To determine the approximate size of the peptides containing or
binding Met-enkephalin, plasma was filtered on a Diaflo Ultrafilters
PM30 membrane. The filtrate (cutoff < 30,000 D) obtained by wash-
ing the membrane with saline was collected separately and subjected to
enzymic hydrolysis with trypsin and carboxypeptidase B before mea-
surement of Met-enkephalin by RIA. Subsequently, a portion of the
eluate from Amicon membranes was mixed with Affi-Gel Blue in
order to separate Met-enkephalin-associated albumin from Met-en-
Table I. Generation of Immunoreactive Met-enkephalin
on Incubation of Plasma (I ml) with Varying Concentrations
of Trypsin and Carboxypeptidase B
Trypsin
ag/mt
Carboxypeptidase B 300 500 1,000 2,000
Ag/ml pM
10 350 600 1,550 1,550
20 200 950 2,250 2,000
50 5,000 -
100 4,450
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kephalin associated with other proteins. 2 ml of saline eluate from
Amicon membranes containing 800 ,l of plasma equivalents was in-
cubated for 2 h with 5 ml Affi-Gel Blue; the slurry was centrifuged for 2
min at 900 g and the supernatant I was collected. The pellet was
washed four times in 3 ml of sodium phosphate buffer 0.02 M, pH 7.1,
centrifuged, and resuspended between each wash and the washes com-
bined. The washed pellet was resuspended in 3 ml of sodium chloride
1.4 Min phosphate buffer, incubated for 2 h at 4VC, and then centri-
fuged, and the supernatant II was collected. Supernatant I, washings,
and supernatant II were lyophilized and hydrolyzed separately with
trypsin and carboxypeptidase B before measurement of Met-enkepha-
fin by RIA. In a subsequent experiment, we compared the amount of
peptidase-derivable Met-enkephalin released from filtrate and reten-
tate, after filtration through a Centricon-100 (Amicon Corp.) mem-
brane, of plasma which had been pretreated with guanidine 6 Mplus
mercaptoethanol 1 Mvs. untreated plasma.
1 ml of rat plasma was dialyzed overnight through a Spectrapor
membrane tubing (cutoff 10,000-12,000 D) against 2 liters of sodium
phosphate buffer 0.02 M, pH 7.1. Separation of Met-enkephalin asso-
ciated with protein or peptide > 12,000 Dwas carried out by size-ex-
clusion chromatography; 250 Al of this dialysate was applied to Sepha-
dex G-200 fine column 1.5 X 80 cm. Fractions of 2 ml of sodium
phosphate buffer 0.02 M(0.2 ml/min) were collected. Aliquots taken
for spectrophotometric assay of protein (Lowry) showed presence of
two major protein peaks. Fractions were lyophilized and hydrolyzed
with trypsin and carboxypeptidase B before measurement of Met-en-
kephalin by RIA. The chromatography on Sephadex G-200 fine col-
umn was repeated three times.
Bioactivity ofpeptidase-derivable Met-enkephalin. 60 ml of human
plasma were digested with trypsin and carboxypeptidase B in our usual
manner as described above to release total Met-enkephalin. After ex-
traction on Porapak Q column and lyophilization of the eluate, the
total Met-enkephalin was run on reverse-phase HPLC as described
above. Fractions corresponding to Met-enkephalin and to Met-en-
kephalin sulfoxide were lyophilized individually, then dissolved in
Krebs-Henseleit buffer for assay of bioactivity on mouse vas deferens
(14). The ability of standard Met-enkephalin and Met-enkephalin ob-
tained by peptidic hydrolysis of plasma to inhibit electrically induced
contraction of strips of mouse vas deferens were compared in an assay
kindly carried out with Drs. R. Altiere, A. Houdi, and J. Kiritsy-Roy
(University of Kentucky). Aliquots representing three different plasma
volumes covering a sevenfold range were compared in duplicate with
four concentrations of Met-enkephalin standard.
Animal studies. Adult male Sprague-Dawley rats (Harlan-Sprague-
Dawley, Inc., Indianapolis, IN) weighing 300-315 g were housed indi-
vidually in an environmental room at 24°C with controlled light-dark
cycles (lights from 0700 to 1900 h) and provided free access to food and
water. 3 d before experimentation, rats received under Equithesin an-
esthesia an indwelling left carotid artery cannula which allowed sam-
pling of blood and injection of drugs at intervals in conscious, freely
moving animals without stress (I15). A series of studies was carried out
in which we examined: (a) the time courses of the plasma native and
peptidase-derivable Met-enkephalin and catecholamine responses to
brief and prolonged restraint stress; (b) the effect of frequent blood
sampling on the levels of these parameters; (c) the effect of repeated
restraint on the plasma Met-enkephalin and catecholamine responses
to acute restraint stress. In all experiments, groups comprised 7-1 1
animals. In order to establish the time course of plasma Met-enkepha-
lin responses to restraint stress, rats were stressed by placing them in
plexiglass restraining holders (16) for 2 (one experiment), 10 (five
experiments), or 30 min (five experiments). Blood was taken from
control and experimental animals at 1 min before stress and at a
number of intervals from 0.5 to 60 min after the onset of stress. Data
from 11 experiments were combined to provide complete time
courses. The maximum blood volume withdrawn at any time point
was 0.8 ml and the maximum blood volume withdrawn from one rat
in any experiment was 3.5 ml. The effect of frequent blood sampling
on the levels of Met-enkephalin was examined using several protocols
in these experiments. In two experiments, 260 Ml of blood was with-
drawn from control and stressed rats at 1 min before stress and at 0.5,
1, 1.5, 2, 2.5, 3, 5, 7, and 10 min after the onset of stress. In other
experiments, 0.5 ml was withdrawn at 1 min before stress and at 2, 10,
20, and 30 min after the onset of stress, or 0.8 ml was withdrawn at 1
min before stress and at 1, 15, and 30 min after the onset of stress.
In order to determine whether repeated application of stress alters
the plasma Met-enkephalin responses to stress, rats were stressed 30
min daily for 7 d by restraining in plastic holders. Blood was collected
on days 1 and 7 at 1 min before and 1, 15, and 30 min after the onset of
stress.
Data analysis. Data were analyzed by analysis of variance and
Duncan's multiple range test.
Results
Characterization ofRIA for Met-enkephalin in plasma. Recov-
ery of Met-enkephalin standard over range of 0.4-200 pg in
the RIA including extraction from Porapak Qwas 80% from
buffer and 95% from 1 ml of acidified plasma (after subtrac-
tion of the endogenous Met-enkephalin in this plasma). When
standard Met-enkephalin was prepared in 0.5 N HCO (to
mimic acidification conditions for handling the plasma), then
brought to pH 6 with buffer, extracted on Porapak Q, and
assayed, recovery was 75%. Recovery of '25I-Met-enkephalin
(20,000 cpm, - 5 pg) from Porapak Qwas 80.0±3.1%; these
data suggest that recovery of Met-enkephalin is absolute from
aspects of the assay procedure other than extraction on Pora-
pak Q (Fig. 1). Intra- and interassay coefficients of variation
are 7%and 1 1%, respectively.
Cross-reactivity of a number of related peptides with anti-
serum to Met-enkephalin was studied (Fig. 2). Using 1 pmol of
peptide, cross-reactivities were: Met-O-enkephalin sulfoxide,
160%; peptide F, 22%; peptide E, 2%; Leu-enkephalin, 1.8%;
peptide B, 0.8%; Met-enkephalin-Arg6-Phe7, 0.6%; Met-en-
kephalin-Arg6-Gly7-Leu8, 0.1%; metorphamide, 0.09%; pep-
tide BAM12P, 0.07%; Tyr-Gly-Gly-Phe and Gly-Gly-Phe-
Met, < 0.01%. Thus, only Met-enkephalin sulfoxide and pep-
tide F showed significant cross-reactivity with this
Met-enkephalin antiserum.
Parallelism of native endogenous Met-enkephalin in
plasma of rat, human, and dog with Met-enkephalin standard
is demonstrated in Fig. 3.
Characterization ofplasma native immunoreactive Met-en-
kephalin. Reverse-phase HPLC of standard Met-enkephalin
consistently reveals two peaks of immunoreactive Met-en-
kephalin in both systems. The first peak coelutes with Met-en-
kephalin sulfoxide and the second peak with Met-enkephalin.
The relative proportion of these two peaks to each other varied
considerably from one study to another; it appears that Met-
enkephalin is variably converted to its sulfoxide during stor-
age, lyophilization, Porapak Q extraction, and HPLC. HPLC
of rat plasma also consistently reveals two peaks of immunore-
active Met-enkephalin, the first peak also coeluting with Met-
enkephalin sulfoxide and the second peak with Met-enkepha-
lin. Fig. 4 presents an example of HPLCof rat plasma spiked
with standard Met-enkephalin which had been extracted and
chromatographed in duplicate. In this particular example, a
third small peak intermediate between the other two was noted
in each of the duplicate plasma samples; however, this small
peak was not a consistent finding in other experiments.
Characterization of peptidase-derivable Met-enkephalin in
plasma. Peptidase-derivable Met-enkephalin refers to cryptic
Met-enkephalin present in larger peptides or proteins, or asso-
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Figure 2. Cross-reactivity of enkephalin-related peptides with Met-
enkephalin antiserum. (A) Met-enkephalin (0). (B) Met-O-enkepha-
lin (o). (C) Peptide F (A). (D) Leu-enkephalin (A). (E) Peptide E
(0 ). (F) Peptide B (e). (G) Met-enkephalin-Arg6-Phe' (*). (H) Me-
torphamide (v); (I) Met-enkephalin-Arg6-Gly7-Leu8 (). (J)
BAM-12P (a). (K, L) Tyr-Gly-Gly-Phe; Gly-Gly-Phe-Met (v).
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Figure 1. Recovery of Met-en-
kephalin standard from Porapak
Q. (A) Standard Met-enkephalin
prepared in buffer, pH 6.5, unex-
tracted [o]. (B) Standard Met-en-
kephalin prepared in acidified
plasma and buffered to pH 6.5,
extracted from Porapak Q [A]. (C)
Standard Met-enkephalin pre-
pared in buffer, pH 6.5, extracted
from Porapak Q [.]. Molar con-
versions for Met-enkephalin stan-
dard on the x-axis are 0.35, 0.9,
1.7, 3.5, 8.7, 17.4, and 35 fmol.
ciated with protein, and which can be generated by enzymic
hydrolysis With trypsin and carboxypeptidase B. Treatment of
plasma consecutively with trypsin and carboxypeptidase B re-
sults in a substantial increase in Met-enkephalin concentra-
tion. Using the hydrolytic conditions described previously (4,
17), we found an increase in plasma Met-enkephalin from
7.1±0.4 (native) to 26.1±2.1 pM (total). However, when we
optimized these hydrolytic conditions, we obtained a much
larger concentration of total Met-enkephalin (Table I). Cur-
rently, for generation of total Met-enkephalin in plasma we
use incubation for 30 min with trypsin 1,000 Ag/ml followed
by incubation for 15 min with carboxypeptidase B 50 Ag/ml
plus trypsin inhibitor 2,500 #gWml. Addition of cobalt chloride
0.1-50 mMto the incubation with carboxypeptidase B did not
enhance the generation of Met-enkephalin. Wehave found
subsequently that addition of cobalt chloride 1 mMto the
incubation with trypsin does enhance the generation of Met-
enkephalin. Identical concentrations of peptidase-derivable
Met-enkephalin were obtained using plasma volumes over a
range of 0.01-0.5 ml. Parallelism of total endogenous pepti-
dase-derivable Met-enkephalin in plasma of rats, humans, and
dogs with Met-enkephalin standard is demonstrated in Fig. 5.
Reverse-phase HPLCof rat plasma which had been treated
sequentially with trypsin then carboxypeptidase B revealed
with both systems used the presence of only two peaks of
immunoreactive Met-enkephalin similar to those found for
native Met-enkephalin; one peak coeluted with Met-enkepha-
lin sulfoxide and the other coeluted with Met-enkephalin. On
the other hand, reverse-phase HPLCof rat plasma followed by
hydrolysis of each fraction with trypsin and carboxypeptidase
B did not reveal any more Met-enkephalin or Met-enkephalin
sulfoxide than was seen with measurement of the native Met-
enkephalin in the corresponding fractions without hydrolysis.
These data support the authenticity of this peptidase-derivable
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immunoreactive Met-enkephalin as native Met-enkephalin
pentapeptide and its sulfoxide, and suggest that the peptidase-
derivable Met-enkephalin is contained within a larger peptide.
Enzymic hydrolysis with trypsin then with carboxypepti-
dase B could be expected to release a number of intermediate























Figure 4. Reverse-phase HPLCof rat plasma (0.8 ml) spiked with
standard Met-enkephalin (100 pg) and extracted on Porapak Q.
Fractions represent collection for 1 min. From HPLCof unspiked
plasma, it could be determined that approximately half of the immu-






Figure 3. Parallelism of native endog-
enous Met-enkephalin in plasma of
I the rat, human, and dog with Met-en-
1000 kephalin standard. Molar conversions
for Met-enkephalin standard on the
x-axis are 1.7, 17, 174, and 1743 fmol.
alin. Weexamined the effectiveness of our hydrolytic condi-
tions to cleave a number of known proenkephalin A-derived
peptides (Table II). The smaller peptides, Met-enkephalin-
Arg6-Phe7, Met-enkephalin-Arg6-Gly7-Leu8 and metorpha-
mide, were cleaved to Met-enkephalin more readily and more
completely than the larger peptides, peptides B, E, and F.
Guanidine hydrochloride 6 M, urea 8 M, and mercap-
toethanol 1 M, were ineffective in generating from plasma the
large amount of immunoreactive Met-enkephalin derived by
proteolytic cleavage with trypsin and carboxypeptidase B
(Table III). However, guanidine and mercaptoethanol did gen-
erate a small amount of Met-enkephalin from plasma, in-
creasing the native concentration about 2.5-fold and 4-fold,
respectively. Guanidine together with mercaptoethanol did
not generate more Met-enkephalin than mercaptoethanol
alone.
Plasma was filtered through a membrane with cutoff mo-
lecular mass < 30,000 D. Hydrolysis of the filtrate containing
peptides with molecular mass < 30,000 D provided < 1% of
the total Met-enkephalin. Met-enkephalin found after hydro-
lysis of the washings of the membrane which contained pep-
tides and proteins of > 30,000 D released > 99% of the total
Met-enkephalin (Table IV). Wecarried out a further experi-
ment in which we filtered plasma through a membrane with
cutoff molecular mass < 100,000 D. Pretreatment of plasma
with guanidine plus mercaptoethanol failed to increase the
amount of either native or peptidase-hydrolyzable Met-en-
kephalin which was filtered or the amount remaining in the
retentate. Affi-Gel Blue chromatography was used to separate
albumin from other proteins in the fraction containing pep-
tides and proteins of molecular mass > 30,000 D. Enzymic
hydrolysis of the supernatant obtained from centrifugation of
the washed and resuspended Affi-Gel Blue pellet and, which
contains mainly albumin, provided only 14% of total pepti-
dase-derivable Met-enkephalin. In contrast, hydrolysis of the
initial supernatant plus the washings from Affi-Gel Blue chro-
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matography (containing proteins of molecular mass > 30,000
D other than albumin) revealed 86% of total Met-enkephalin.
These results were confirmed by gel chromatography of
plasma on Sephadex G-200 fine column. Enzymic hydrolysis
with trypsin and carboxypeptidase B revealed the largest peak
(65% of total) of immunoreactive Met-enkephalin in fractions
16-23 (Fig. 6 C) corresponding to the globulin peak of plasma
protein (Fig. 6 A) and approximately with our thyroglobulin
standard, molecular mass 669,000 D (Fig. 6 B). A second large
Met-enkephalin peak (22% of total) was found in fractions
32-37 corresponding to the albumin standard (67,000 D) and
to the albumin peak of plasma protein. A third small peak
(1 1%) of Met-enkephalin in fractions 28-31 corresponded to a
Table II. Generation of Peptidase-derived Met-enkephalin
from Enkephalin-related Peptides





Peptide B 3 1
Peptide E 4 4
Peptide F 4 7
D-Ala2-Met-enkephalinamide 0 0
Data are presented as percent of peptide converted to immunoreac-
tive Met-enkephalin.
Either 1 or 10 ng of peptide was incubated sequentially with trypsin
10 ,tg and carboxypeptidase B 1 Mg, and the medium assayed for
Met-enkephalin. The data were corrected for recovery by incubation




Figure 5. Parallelism of endogenous
peptidase-derivable enkephalin in rat,
d human, and dog plasma with Met-en-
1000 kephalin standard. Molar conversions
for Met-enkephalin standard on the
x-axis are 1.7, 17, 174, and 1743 fmol.
shoulder on the front of the albumin peak of plasma proteins
and to protein of molecular mass 100,000-150,000 D. It is
unclear whether two other peaks of Met-enkephalin were pres-
ent on the back shoulder of the larger globulin peak between
250,000 and 500,000 D. These findings of multiple high mo-
lecular mass protein peaks which release immunoreactive
Met-enkephalin upon peptidic hydrolysis were replicated on
Sephadex G-200 chromatography on three separate occasions.
Bioactivity of peptidase-derivable Met-enkephalin. Plasma
extract which had been hydrolyzed with trypsin and carboxy-
peptidase B to release total Met-enkephalin and extracted on
Porapak Q was run on reverse-phase HPLC. Fractions repre-
senting Met-enkephalin and Met-enkephalin sulfoxide were
studied individually in a mouse vas deferens assay to quanti-
tate bioactive Met-enkephalin. The responses of authentic
Met-enkephalin pentapeptide obtained from aliquots repre-
senting 11.2 and 22.4 ml of plasma are compared with the
responses to Met-enkephalin standard in Fig. 7. These data
provided an estimate for plasma concentration of bioactive
peptidase-derivable Met-enkephalin of 3,973 pM; very compa-
rable to our estimates of plasma concentration of immunore-
active Met-enkephalin. Met-enkephalin sulfoxide isolated by
HPLCfrom the enzymically hydrolyzed plasma pool appeared
to be at least as potent in this bioassay system as the similarly
isolated Met-enkephalin. Furthermore, the effects of both
plasma peptidase-derivable Met-enkephalin and its sulfoxide
to inhibit electrically-induced contraction of mouse vas defer-
ens were reversed completely by addition of naloxone to the
perfusion bath at a time when the peptides were maximally
active.
Plasma Met-enkephalin responses to restraint stress. Time
courses of plasma native and peptidase-derivable Met-enkeph-
alin responses to restraint stress are shown in Fig. 8; each point
represents the mean of 2-10 different experiments with 7-111
rats in each experiment. Plasma native Met-enkephalin level
increased from a basal level of 9.6±0.8 pM(mean±SEM) to a
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Table III. Generation of Immunoreactive Met-enkephalin by Protein-disrupting Agents
Met-enkephalin concentration
Trypsin plus
Native carboxypeptidase B Urea, 8 M Guanidine, 6 M Mercaptoethanol, I M Guanidine plus mercaptoethanol*
pM
Experiment 1 29 3.779 35 82
40 4,960 44 161
Experiment 2 31 2,395 - 65 172
43 2,468 72 155
Experiment 3 47 1,987 137
27 1,832 - 174
* Guanidine 6 Mplus mercaptoethanol 1, 5, or 10 Mgave identical results.
peak of 30.2±10.4 pM (P < 0.01) at 0.5 min of restraint and
remained elevated only briefly. In spite of continuation of
stress, plasma level of native Met-enkephalin declined to 18
pMby 2 min, 15 pMby 2.5 min, and 12.5 pMby 5 min, and it
was not different from basal level at this time. Prolonged re-
straint produced a second peak of plasma native Met-enkepha-
lin at 30 min of stress. Plasma level of Met-enkephalin in-
creased from 9.2±1.7 pM at 20 min of restraint to 27.9±4.0
pMat 30 min (P < 0.01). 10 min after the end of 30 min of
restraint stress, plasma native Met-enkephalin level was no
different from that seen in control animals. Immediately after
the 60 min period of restraint, rats were decapitated. Plasma
concentrations of both native (8.0±1.2 pM) and peptidase-
derivable (5,294±655 pM) Met-enkephalin in trunk blood at
this time were identical to those in blood taken from the arte-
rial cannula at 60 min of restraint.
Nonstressed control animals did not show any significant
changes in plasma level of native Met-enkephalin during the
entire period of the experiments. Since withdrawal of large
volumes of blood may result in sympathoadrenal activation, it
was necessary to demonstrate that our blood sampling proto-
cols did not increase plasma Met-enkephalin concentration.
The effect of repeated blood sampling on plasma Met-enkeph-
alin levels was examined using several protocols in these ex-
periments. Neither frequent withdrawals of a small volume
(0.26 ml) for a total withdrawal of 2.6 ml of blood over 10 min
in 300-g rats nor less frequent withdrawals of larger volumes
(0.5-0.8 ml) for a total withdrawal of 3.5 ml of blood over 30
min resulted in elevation of plasma native Met-enkephalin.
Similar to native Met-enkephalin, plasma peptidase-deriv-
able Met-enkephalin response was maximal at 0.5 min of re-
straint, increasing from a basal level of 3,450 to a peak of 5,260
pM, but this response was somewhat more prolonged than that
for native Met-enkephalin. Plasma peptidase-derivable Met-
enkephalin returned to basal level by 7 min. Plasma pepti-
dase-derivable Met-enkephalin again showed an elevated level
at 30 min of restraint stress (from 3,193+49 to 4,289±76 pM),
but this response was much less than the initial response at 0.5
min of stress. Plasma peptidase-derivable Met-enkephalin
levels in control unstressed animals did not show any statisti-
cally significant differences during the experiment. Also simi-
lar to native Met-enkephalin, our blood sampling protocols
did not produce changes in plasma concentration of total
Met-enkephalin.
Time courses of plasma norepinephrine and epinephrine
responses to restraint stress are shown in Fig. 9; each value is
the mean of one to eight different experiments. Plasma norepi-
nephrine increased from a basal level of 1.45+0.15 to a peak of
5.19±0.39 nM, also at 0.5 min of restraint. The peak plasma
level of norepinephrine lasted for the next 0.5 min of stress (P
< 0.01), then declined slowly but still remained significantly (P
< 0.05) elevated to the end of the 30 min of restraint. Plasma
epinephrine increased from a basal level of 1.68±0.24 to a
peak of 12.69±0.64 nM, also at 0.5 min of restraint, then
decreased to 6.42±0.81 nMby 2 min and declined slowly to
4.9± 1.0 nM by 30 min of stress; this concentration was still
elevated above basal level (P < 0.01). Control animals did not
show any significant changes in the plasma concentrations of
norepinephrine and epinephrine during experiments.
Since it has been demonstrated that repeated administra-
tion of an identical stressor resulted in adaptation of catechol-
amine responses (18), it was of interest to study possible
Table IV. Distribution of Total Peptidase-derived Met-enkephalin Associated with Proteins in Rat Plasma
Separation technique Molecular mass Met-enkephalin concentration Recovery
D pM %
Filtration through Amicon Diaflo <30,000 38
Ultra-filters PM30membrane >30,000 4,706 95
Affi-gel blue chromatography Albumin (67,000) 627
>67,000 4,009 93
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Figure 6. Chromatograms of rat plasma and protein standards on
Sephadex G-200 fine column. (A) protein (Lowry), mg/I00 ml of
plasma; (B) ultraviolet absorbance of protein standards and plasma;
(C) Met-enkephalin immunoreactivity, pg/ml.
changes in the plasma native and peptidase-derivable Met-en-
kephalin responses to repeated exposure to restraint stress.
Thus, rats were exposed to restraint stress daily for 30 min, and
plasma Met-enkephalin and catecholamine responses were
measured. Plasma native and peptidase-derivable Met-en-
kephalin responses to initial, acute 30 min restraint on days 1
and 7 after 1 wk of daily exposure to 30 min restraint are
shown in Fig. 10. Acute restraint stress increased rapidly the
plasma level of native Met-enkephalin from a basal value of
8.9±0.8 to 30.7±3.1 pM at 1 min (P < 0.01). As shown pre-
viously in time course experiments, plasma level of native
Met-enkephalin declined after a transient elevation, and by 10
min of restraint was not different from basal level. Also, pro-
longed stress to 30 min caused a second increase of plasma
native Met-enkephalin level up to 21.3±2.2 pMat the end of
restraint. Repeated daily exposure to 30 min of restraint stress
for 1 wk resulted in complete loss of the plasma native Met-en-
kephalin response to acute restraint.
Acute restraint stress increased plasma concentrations of
peptidase-derivable Met-enkephalin from a basal level of
3,337+127 to a peak of 4508±293 pM at 1 min (P < 0.01).
Met-enkephalin remained elevated at 15 min of stress
I II
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Figure 7. Bioactivity of plasma peptidase-derivable Met-enkephalin.
The effects of standard Met-enkephalin and Met-enkephalin gener-
ated by enzymic hydrolysis of plasma to inhibit electrically-induced
contraction of mouse vas deferens in vitro are compared.
(4,127±270 pM, P < 0.05) and again increased further at 30
min of stress to 4,480±239 pM. The basal level of plasma
peptidase-derivable Met-enkephalin on day 7 was elevated,
but this increase was not statistically significant. Rats exposed
to restraint stress for 30 min daily for 1 wk showed a tendency
on day 7 to increase plasma levels of peptidase-derivable Met-
enkephalin, but the increases were not statistically significant.
Plasma levels of peptidase-derivable Met-enkephalin in the
control unstressed animals did not show any changes during
blood sampling, either on day 1 or 7.
Plasma epinephrine and norepinephrine responses to acute
restraint stress, initially and after 1 wk of daily stress, are com-
pared in Fig. 11. Acute 30 min restraint on day 1 produced a
maximal increase in plasma concentration of epinephrine
from a basal level of 0.9±0.27 to a peak of 10.07±1.22 nM(P
< 0.01) at 1 min of stress. As noted above, plasma epinephrine
declined somewhat but remained significantly elevated above
basal level throughout the period of acute restraint. After 1 wk
of daily restraint stress, the plasma epinephrine response to
restraint on day 7 was blunted when compared to the response
on day 1, but the epinephrine response remained statistically
significant at 1 and at 30 min of stress. Plasma norepinephrine
response to initial restraint was similar to that described in the
experiments above. After a maximal increase seen at 1 min,
plasma norepinephrine had decreased by 15 min but was still
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Figure 8. Plasma immunoreactive Met-enkephalin responses to re-
straint stress. Data from 11 experiments were combined; numbers in-
dicate numbers of experiments at each time point with 7-1 1 rats per
experiment. (o) Control; (.) restraint. Data were analyzed by
ANOVAand Duncan's multiple range test. After stress, statistically
significant differences from baseline were present at 0.5, 1, 2, 2.5,
and 30 min for native and at 0.5, 1, 1.5, 2, 3, 5, and 30 min for pep-
tidase-derivable Met-enkephalin. No significant differences were
noted in control unstressed rats.
significantly elevated above baseline at the end of the 30-min
stress. In contrast to epinephrine, on day 7 plasma norepi-
nephrine did increase significantly above the basal concentra-
tion but did not remain elevated throughout the 30-min period
of stress.
Discussion
Wehave described a very sensitive method for measurement
in plasma (and other biological fluids) of native and pepti-
dase-derivable Met-enkephalin. This method employs a com-
mercial antiserum and a tracer radiolabeled either commer-
cially or in our laboratory. Radioimmunoassays for Met-en-
kephalin described previously have reported a wide range for
basal plasma concentration (8). This variation may relate to
differences in methods of blood collection, in methods of ex-
traction of peptide from plasma, and in antisera.
Previously, we had found that published methods of blood
collection for Met-enkephalin were not optimal, and we intro-
duced the use of citrate to prevent degradation of the penta-
peptide (12). We found citrate to be more effective in this
regard than the specific aminopeptidase inhibitor, bestatin,
and subsequently we reduced the final concentration of citrate
from 23 to 17 mMto prevent hemolysis which occurs with
citrate in some blood, particularly sheep blood. Wealso use
aprotinin to prevent degradation of large precursor peptides to
Met-enkephalin. In unpublished studies, we found that addi-
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Figure 9. Plasma catecholamine responses to restraint stress. Data
from eight experiments were combined; numbers indicate numbers
of experiments at each time point. (o) control; (e) restraint. Data
were analyzed by ANOVAand Duncan's multiple range Test. After
stress, statistically significant differences from baseline were present
at 0.5, 1, 2, 10, and 30 min for both native and peptidase-derivable



























Figure 10. Plasma native and total peptidase-derivable Met-enkepha-
lin responses to initial (day 1, .) and repeated daily (day 7, o) 30-min
restraint stress (x±SEM). *Significant difference at P < 0.05 from
basal concentration at time -1 min. Significant difference at P
< 0.05 from concentration at corresponding day 7 time point. *Sig-
nificant change at P < 0.01 for the overall curve from baseline.
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Figure 11. Plasma epinephrine and norepin
tial (day 1, *) and repeated daily (day 7, o)
(i±SEM). *Significant difference at P < 0.0
tion at time -1 min. Significant difference
centration at corresponding day 7 time poir
the overall curve from baseline at P < 0.01.
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was even more immunoreactive thai
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Met-enkephalin in human plasma. Sii
plasma has not been reported.
Incubation of adrenal cell culture n
with the peptidases, trypsin and carbx
Met-enkephalin from proenkephalin /
INE peptidic intermediates. Peptidic hydrolysis of large peptides
and proteins in plasma may yield a number of biologically
CONTROL active peptides (8, 10, 22, 25, 26). Thus, extracellular and even
intravascular production of peptides by limited proteolytic
cleavage from secreted precursors may represent a physiologic
mechanism of origin of bioactive peptides. Proteases such as
trypsin may act in a manner similar to an enzyme such as
kallikrein which physiologically processes kininogen to brady-
kinin-related peptides (27, 28). Potential cleavage sites and
proteolytic mechanisms have been reviewed elsewhere (10, 25,
27, 28). As we noted above, incubation of plasma with con-
centrations of trypsin and carboxypeptidase B used in those
published studies increased the yield of immunoreactive Met-
enkephalin by about threefold. When we increased the con-
centration of these peptidases to a more optimal level, we
RINE increased the yield of Met-enkephalin from plasma greatly to
350-fold. Furthermore, we have found that acid hydrolysis
using lyophilization of plasma in strong acid also yields large
amounts of immunoreactive Met-enkephalin in plasma (29).
In contrast to the report of Singer et al. (22), we were unable to
increase plasma concentrations of Met-enkephalin by incuba-
tion with pepsin. Apparently, these investigators were unable
to generate increases in Met-enkephalin concentration in
0 15 30 plasma using trypsin and carboxypeptidase B, although it
as) seems that they did not use trypsin inhibitor together with
carboxypeptidase B and they used much lower concentrations
ephrine responses to ini- of these peptidases. Also, the findings of Singer et al. (22) of
30-min restraint stress pepsin-induced generation of immunoreactive Met-enkepha-
15 from basal concentra- lin from plasma may relate in part to their incubation and
at P < 0.05 from con- lyophilization of plasma at low pH. Finally, their use of acid-
nt. ~Significant change for acetone extraction of plasma may alter the yield of Met-en-
kephalin from plasma. Recently, Giraud et al. (30) described
generation of Met-enkephalin-Arg6-Phe7 from rat plasma
not affect immunoreac- using pepsin. Although the antiserum used in our studies does
rver, collection of blood not cross-react significantly with Met-enkephalin-Arg6-Phe7,
;o citrate and aprotinin we have found that trypsin followed by carboxypeptidase B
immunoreactive pepti- will cleave a significant portion of this heptapeptide to Met-en-
we found in their ab- kephalin (Table II).
mportant step in main- Neither arylsulfatase nor fl-glucuronidase generated Met-
i in plasma. enkephalin from plasma (29), suggesting that Met-enkephalin
styrene and ethylvinyl- does not circulate in significant concentration as a conjugate of
zene, has been reported either sulfate or glucuronide. Incubation of plasma with gua-
ins (12, 19). Wefound nidine hydrochloride generated a small amount of Met-en-
g Met-enkephalin from kephalin, suggesting that this small amount of Met-enkephalin
heep. We(unpublished) might circulate in noncovalent association with albumin. Also,
nuch less effective; also, generation of a small amount of native Met-enkephalin by
for recovery of Met-en- incubation of plasma with mercaptoethanol suggests that some
one extraction has been Met-enkephalin is linked to protein by disulfide bonds. How-
of plasma or very high ever, none of guanidine hydrochloride, urea, or mercaptoeth-
available (22). anol generated the large amount of Met-enkephalin seen fol-
have employed antisera lowing enzymic cleavage with trypsin and carboxypeptidase B,
sulfoxide which do not suggesting further that this total peptidase-derivable Met-en-
Dquire oxidation of sam- kephalin in plasma is not present simply in noncovalent or
-O-enkephalin sulfoxide disulfide bonding to protein. Also, pretreatment of plasma
n Met-enkephalin. The with guanidine plus mercaptoethanol, before their filtration
-ross-reactivity of note through a membrane with cutoff of molecular mass < 100,000
al. (23) reported plasma Ddid not result in an increase in Met-enkephalin which could
ly higher than those of be released by peptidic hydrolysis; these data suggest that this
milar comparison in rat peptidase-derivable Met-enkephalin is not present simply in
proenkephalin A bound noncovalently to larger proteins. Fur-
nedium (4) or tissue (24) thermore, it seems likely that the Met-enkephalin sequence is
)xypeptidase B, releases present near the amino or carboxy terminus of the protein or
k and from a number of in a loop sequence since it is so readily released by trypsin, and
870 K Pierzchala and G. R. Van Loon
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it is probably on the surface of the protein since it does not
require denaturation for its release.
Wedemonstrated on mouse vas deferens that both pepti-
dase-derivable Met-enkephalin and its sulfoxide had nalox-
one-reversible bioactivity comparable to that of synthetic
Met-enkephalin. These data provided further confirmation for
our radioimmunoassay and HPLC findings that this pepti-
dase-derivable Met-enkephalin was indeed authentic Met-en-
kephalin pentapeptide. Previously, we had also shown that
total immunoreactive Met-enkephalin derived in the same
manner by enzymic hydrolysis with trypsin and carboxypepti-
dase B from brain tissue was bioactive (31). The data also
suggest that this pool of peptidase-derivable Met-enkephalin in
plasma may provide a very significant source of bioactive
Met-enkephalin.
Chromatography of rat plasma on Sephadex G-200 yielded
two or three major protein peaks, one in the molecular mass
range of 600,000 D and another at 67,000 D with a
shoulder running up to 150,000 D. After Sephadex G-200
chromatography, digestion of fractions with trypsin and car-
boxypeptidase B yielded a large peak of immunoreactive Met-
enkephalin at a position corresponding to globulins or other
proteins of molecular mass 600,000-700,000 D, a smaller
peak corresponding to albumin and several even smaller and
questionable peaks in between. Boarder et al. (32) found only
small amounts of Met-enkephalin-like material associated
with peptides of > 12,000 D in human plasma. Singer et al.
(22) found in pepsin-treated plasma a single peak of Met-en-
kephalin immunoreactivity corresponding to a protein of mo-
lecular mass - 65,000 D. Wehave found that a significant
quantity of immunoreactive Met-enkephalin can be generated
from bovine serum albumin by sequential incubation with
trypsin and carboxypeptidase B. Shen and Lindberg (33) gen-
erated from rat serum albumin a peptide which was immuno-
reactive in their Met-enkephalin RIA, but which was more
hydrophilic and had a different pl from authentic Met-en-
kephalin. Our data with both Sephadex G-200 chromatogra-
phy and with Affi-Gel Blue chromatography suggested that
14-22% of the immunoreactive Met-enkephalin which we
generated from plasma derived from albumin or a protein of
similar molecular weight. Thus, it appears that trypsin (in our
hands) or pepsin (in the hands of other investigators [22, 33]
but not in our hands) are able to lyse albumin or a closely
related protein to yield immunoreactive Met-enkephalin. The
major peak of immunoreactive Met-enkephalin which we ob-
tained upon sequential digestion with trypsin and carboxy-
peptidase B of fractions from Sephadex G-200 chromatogra-
phy of rat plasma was not albumin, but rather a protein of the
size of a globulin with molecular mass > 600,000 D. In any
case, and while it is not possible to entirely rule out the possi-
bility that preproenkephalin A is bound to a large protein, it is
clear from our studies and from those of others (22, 30, 33)
that largely the plasma protein precursors for peptidase-deriv-
able Met-enkephalin and related peptides differ structurally
and chemically from proenkephalin A.
Possenti et al. (34) provided evidence that enkephalins are
bound to protein in plasma. However, the type of binding
remains obscure. From the conditions required to generate the
large amounts of enkephalin-related peptides from plasma in
our studies and in those of others (22, 30, 33), it seems proba-
ble that this immunoreactive Met-enkephalin is either an in-
trinsic part of the protein molecules or is very strongly bound
to proteins. Renin is a 40,000-D molecular mass protein which
may also exist in plasma as an 800,000-D protein (35), proba-
bly in complex with a number of binding proteins including
a2-macroglobulin (36). It is possible that Met-enkephalin or
preproenkephalin A also are bound strongly in a specific con-
formation with plasma proteins; immunoelectrophoretic
identification of these binding proteins might be facilitated by
unfolding and refolding of labelled preproenkephalin A by
guanidine. Differences between the generation of another
neuropeptide, neurotensin, from brain cells and neurotensin-
related peptides from plasma have been discussed by Carraway
et al. (26). Analogies may exist for neuronal Met-enkephalin
and the peptidase-derivable immunoreactive Met-enkephalin
generated from plasma. Thus, native Met-enkephalin pro-
cessed from proenkephalin A and stored within vesicles in
sympathetic nerves or chromaffin cells is released upon ap-
propriate stimulation. On the other hand, Met-enkephalin or a
closely related immunoreactive peptide present in another
large precursor form in plasma may undergo rapid proteolysis
similar to that seen for generation of bradykinin or angio-
tensin.
Previous studies have documented the co-secretion of im-
munoreactive Met-enkephalin and catecholamines from
chromaffin cells in culture (3, 4), from isolated perfused adre-
nal glands (6, 7), and from dog adrenals in vivo (5). However,
plasma Met-enkephalin responses to stimuli have been docu-
mented in relatively few studies (cf. 8, 37-39). In this study, we
describe in rats consistent rapid increases in plasma immuno-
reactive native Met-enkephalin in response to restraint, a psy-
chological stress. Plasma native Met-enkephalin peaked in
parallel with the increases in plasma epinephrine and norepi-
nephrine. Thereafter, there was a divergence in the plasma
concentrations of Met-enkephalin and catecholamines during
the period of restraint stress. Plasma Met-enkephalin showed a
biphasic response to 30 min of restraint. A somewhat similar
phasic response pattern has been reported for plasma epineph-
rine and norepinephrine in response to hemorrhage, with an
initial peak within 5 min and a second peak at 20-30 min
(40). Also, the apparently rapid clearance of the large molecu-
lar mass proteins which yield the peptidase-derivable Met-en-
kephalin may relate to increased secretion of large protein for
only a very brief period after onset of stress; then, the apparent
clearance of the large protein would in fact reflect clearance of
Met-enkephalin. Whether these phases of Met-enkephalin re-
sponse represent secretion from different compartments in the
same tissue similar to that seen with insulin (41) or secretion
from different tissues remains unknown. It seems probable
that the brief duration of the initial peak of plasma Met-en-
kephalin induced by restraint stress is a result of a central
nervous system regulatory mechanism rather than of a limita-
tion in Met-enkephalin pool size, since the more severe stress
of immobilization produced a prolonged elevation of plasma
Met-enkephalin (42).
The adrenal medulla has seemed to most investigators to
represent the most probable source of circulating Met-enkeph-
alin, and we have found that in dogs adrenal secretion rate of
native Met-enkephalin increases briskly in response to insu-
lin-induced hypoglycemia (8) or nicotine (43). On the other
hand, the adrenomedullary concentration of Met-enkephalin
is considerably lower in rats than in other species (44). We
have carried out a study to determine the sympathetic nerve
and adrenomedullary contributions to the plasma Met-en-
kephalin increases seen in response to restraint in rats (45).
Chemical sympathectomy with guanethidine, but not adrenal
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demedullation, prevented the plasma native Met-enkephalin
response to restraint stress. These data suggest that in rats the
restraint stress-induced increase in plasma native Met-enkeph-
alin is derived largely from sympathetic nerves and not from
the adrenal medulla. It is well known that plasma catechol-
amine concentrations in trunk blood after decapitation are
markedly higher than those in blood taken from an indwelfing
cannula (18), presumably because of massive adrenomedul-
lary discharge associated with decapitation. In contrast,
plasma Met-enkephalin concentration does not appear to be
affected by decapitation in rats. This may also argue against
the adrenal medulla as a major source of circulating Met-en-
.kephalin in rats. Wehave been unable to reduce basal plasma
Met-enkephalin with chemical sympathectomy, adrenal de-
medullation, hypophysectomy, or evisceration (Barron, B.,
and G. R. Van Loon, unpublished results). A small amount of
circulating Met-enkephalin may derive from median emi-
nence since levels are higher in hypothalamohypophyseal por-
tal blood than in peripheral blood (Van Loon, G. R., and P.
Plotsky, unpublished results).
Peptidase-derivable Met-enkephalin showed multiphasic
response patterns to restraint stress which paralleled those for
native Met-enkephalin, although the concentration varied
from 150- to 375-fold higher than for native Met-enkephalin.
The origin of the stress-induced increase in plasma peptidase-
derivable Met-enkephalin is more difficult to understand than
is the origin of the stress-induced increase in native Met-en-
kephalin.
Repeated exposure to an identical stressor results in adap-
tive loss of the plasma catecholamine responses to stress ( 18).
Thus, it was of considerable interest to determine whether the
plasma Met-enkephalin responses to repeated exposure to
stress showed a similar adaptation. Sympathoadrenal release
of Met-enkephalin showed rapid adaptation of response; after
6 d of daily 30-min restraint stress, there were no longer
plasma native or peptidase-derivable Met-enkephalin re-
sponses to restraint. Although the plasma epinephrine and
norepinephrine responses to restraint were blunted after 6 d of
daily 30-min restraint stress, they remained significant. This
suggests to us that adaptation of the sympathetic nerve re-
sponses to a psychological stress occurs more readily than ad-
aptation of the adrenomedullary responses. A somewhat dif-
ferent pattern of adaptation of plasma Met-enkephalin re-
sponses was seen with immobilization stress, and both native
and peptidase-derivable Met-enkephalin showed cross-toler-
ance to hemorrhagic or electric footshock stress when adapted
to immobilization (42). It remains unknown whether adapta-
tion of plasma Met-enkephalin responses to restraint or im-
mobilization stress is mediated in brain, in the peripheral
sympathoadrenal Met-enkephalin pool, or in both. A number
of response patterns have been noted during adaptation of
sympathoadrenal responses to chronic stress (46). These in-
clude increased biosynthetic and storage capacity, elevated
basal activity, attenuated responsiveness to homotypic stimu-
lation and similar or potentiated responsiveness to novel stim-
ulation. However, no clear hypothesis has emerged to unify
these observations into a clear explanation of adaptation of the
sympathoadrenal responses to repeated stress.
The function of circulating Met-enkephalin remains elu-
sive, but roles for opioid peptides in neuroendocrine (2) and
cardiovascular regulation (37, 47, 48) as well as modulation of
immune function (49) have been proposed. Although the
plasma concentrations of native Met-enkephalin (5-50 pM)
appear rather low to effectively mediate humoral responses,
nanomolar to micromolar concentrations of peptidase-deriv-
able Met-enkephalin demonstrated in plasma, and changes in
plasma concentration of this peptidase-derivable Met-enkeph-
alin in response to physiologic stimuli, suggest a functional
role.
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